

Children’s Hospital of Philadelphia Designated an Oxalosis & Hyperoxaluria Foundation Care Center of Excellence for Primary Hyperoxaluria

PHILADELPHIA, PA (Jan. 6, 2026) – The [Oxalosis & Hyperoxaluria Foundation](http://www.ohf.org) (OHF) today announced that [Children’s Hospital of Philadelphia](https://www.chop.edu) (CHOP) has been designated an OHF Care Center of Excellence, recognizing the hospital’s expertise in providing specialized, comprehensive care for children and families affected by primary hyperoxaluria (PH), a rare genetic kidney disease.

CHOP is the fifth medical center nationwide and the second pediatric institution to join the OHF Care Center Network, alongside Mayo Clinic, University of Alabama at Birmingham, Boston Children’s Hospital, and University of California San Francisco (UCSF). With three centers added in 2025 and additional designations expected in 2026, the network continues to expand access to expert PH care across the United States.

PH is a rare inherited condition in which the liver produces excessive oxalate, leading to kidney stones, nephrocalcinosis, and progressive kidney damage. Symptoms can appear as early as infancy, and without early diagnosis and appropriate treatment, PH can lead to kidney failure requiring dialysis or combined liver-kidney transplantation.

As an OHF Care Center of Excellence, CHOP follows the latest evidence-based clinical guidelines for PH diagnosis, treatment, and long-term management and offers access to clinical trials for rare stone disorders when available.

“Primary hyperoxaluria is a complex and rare condition that requires early diagnosis and highly specialized care,” said [Gregory Tasian, MD](#), an attending pediatric urologist in the [Division of Urology at CHOP](#). “This designation reflects our commitment to evidence-based care, multidisciplinary collaboration, and long-term support for children and families affected by PH.”

Because PH is ultra-rare and often underdiagnosed, families frequently face challenges finding knowledgeable providers and coordinated care. CHOP’s designation helps address this gap for patients in the Mid-Atlantic region and beyond.

About OHF

The Oxalosis and Hyperoxaluria Foundation is the world’s largest private funder of hyperoxaluria research. Dedicated to finding a cure, OHF puts patients first — advancing research, improving care, and empowering those living with the disease.

www.ohf.org